The 1st China Pharmaceutical Innovation Conference (CPIC 2026)  hosted by Tonacea, will be held July 22–24, 2026 at the National Exhibition and Convention Center (NECC) in Shanghai.

CPIC will establish a model of "China Innovation – Global Partnerships – Shanghai Dealmaking". As the premier gateway for international capital to navigate China’s innovation ecosystem, and a strategic hub for Chinese pharmaceutical companies to scale globally, CPIC will undoubtedly set the benchmark for investment and partnership in the healthcare industry. CPIC will feature dozens of specialized sessions covering hot topics and future directions in healthcare innovation investment and globalization.

Stem cell therapies are rapidly moving from the lab to the clinic. However, scalable, standardized, and cost-effective cell culture processes remain a critical bottleneck determining whether this progress can be truly realized. Co-hosted by Youyi Bio and Tonacea, the "Advanced Stem Cell Culture Process" Symposium schedule is officially released today. The symposium will focus on core topics such as large-scale stem cell expansion, serum-free culture systems, bioreactor design, and process scale-up, inviting leading experts from industry, academia, and clinical practice to share hands-on experience and cutting-edge breakthroughs.

July 22–24 in Shanghai — we look forward to exploring with you the process solutions for stem cell industrialization.

Special Session Agenda

Organizer: Youyi Bio

Moderator：Shang Xiao，Founder & Chairman, Youyi Bio

Culture of MSC: from 2D to 3D, and beyond

Lianming Liao：CSO, Tuohong Bio

High-Efficiency Exosome Production Factory Driven by All-Factor Integrated Medium

Ali Mohsin：VP of R&D, Youyi Bio

Roundtable 1: Implementation of Documents No. 818 and No. 828 – Risks and Challenges in Cell Therapy Supply Chain under Dual Regulatory Frameworks

Yutian Shen: CEO, Saijun Bio

Zhiying He: Distinguished Researcher & Executive Director，Institute for Regenerative Medicine，Shanghai East Hospital of Tongji University

Yonghong Yin: Deputy GM, Sailiwei Bio

Yijie Yang: Co-founder & CEO, Shenzhen Huixin Bio-Medical Technology Co., Ltd.

Yueming Wang: CEO, Yuanxin Excellence Bio; International Advisor, Beijing Daxing International Airport Economic Zone

Ting Zhang: CEO, Gemrisen

Roundtable 2: Compliance and Prospects of MSC Cell Therapy

Wei Wu（Moderator): General Manager, Suzhou Youyi Bio

Chencai Liu: Deputy GM, Qichuang Research Institute

Lin Shi: Chief Medical Officer, Jinfeng Laboratory; former VP of Yuanda Medical; Vice Chairperson, CBIITA Consortium; Professor

Guanghua Yang: Chief Scientist, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Chairman, Heji (Shanghai) Medical Technology Co., Ltd.

Zhang Wenjun: Deputy Director, Institute of Hematology, Tongji University; Deputy Director, Oncology Center, Tongji Hospital; Deputy Director, Institute of Hematology, Tongji University School of Medicine

PAN SWEE TING: Managing Director & Head of China, JIF Capital